Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders.
about
Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitroThe first draft of the endostatin interaction networkHeparan sulfate proteoglycan induces the production of NO and TNF-alpha by murine microglia.Crystal Structure of the E2 Domain of Amyloid Precursor Protein-like Protein 1 in Complex with Sucrose OctasulfateGlycoarray Technologies: Deciphering Interactions from Proteins to Live Cell ResponsesHeparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake.Glycomics approaches for the bioassay and structural analysis of heparin/heparan sulphatesReporter pathway analysis from transcriptome data: Metabolite-centric versus Reaction-centric approach.Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells.Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's diseaseNeuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease.Heparin induces harmless fibril formation in amyloidogenic W7FW14F apomyoglobin and amyloid aggregation in wild-type protein in vitro.The absence of myelin basic protein promotes neuroinflammation and reduces amyloid β-protein accumulation in Tg-5xFAD mice.Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein.N-terminal region of myelin basic protein reduces fibrillar amyloid-β deposition in Tg-5xFAD mice.Single-entity heparan sulfate glycomimetic clusters for therapeutic applications.Extracellular matrix abnormalities in schizophreniaPreclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral AmyloidosisSPECT imaging of peripheral amyloid in mice by targeting hyper-sulfated heparan sulfate proteoglycans with specific scFv antibodies.Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-β in murine brainPhylogenetic and mutational analyses reveal key residues for UDP-glucuronic acid binding and activity of beta1,3-glucuronosyltransferase I (GlcAT-I)Heparan sulfate proteoglycans mediate Aβ-induced oxidative stress and hypercontractility in cultured vascular smooth muscle cellsCatalytically active tissue transglutaminase colocalises with Aβ pathology in Alzheimer's disease mouse models.Folding versus aggregation: polypeptide conformations on competing pathwaysThe extracellular matrix in multiple sclerosis pathology.Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease.Heparan sulphate biosynthesis and disease.Amyloid formation in heterogeneous environments: islet amyloid polypeptide glycosaminoglycan interactionsHeparin accelerates gelsolin amyloidogenesis.Immunomodulatory and anti-inflammatory effects of chondroitin sulphate.Manipulating the extracellular matrix and its role in brain and spinal cord plasticity and repair.ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?Sugar glues for broken neuronsThe effect of glycosaminoglycans (GAGs) on amyloid aggregation and toxicity.Cellular internalization of alpha-synuclein aggregates by cell surface heparan sulfate depends on aggregate conformation and cell typeSusceptibility to neurofibrillary tangles: role of the PTPRD locus and limited pleiotropy with other neuropathologies.Drug-Mediated Regulation of Glycosaminoglycan Biosynthesis.Sulfated glycosaminoglycans in protein aggregation diseases.Molecular interactions of amyloid nanofibrils with biological aggregation modifiers: implications for cytotoxicity mechanisms and biomaterial design.Amyloid plaques beyond Aβ: a survey of the diverse modulators of amyloid aggregation.
P2860
Q24321663-A2425F06-0F7F-44DA-A19C-B7A3DDF8DD75Q24338820-2DE574D9-DA09-4E2C-BDE3-D2F152D7F643Q24813947-669ED16B-DC9F-4D3A-94D5-FD7AA77D7B6CQ27670602-D033FC40-61DB-4FB7-B5E6-FD70D532F741Q28073864-BC0136EC-10F7-4B54-BF0D-57C7EE564061Q29976923-43A7D68B-92E8-4568-8C9C-29E3551ADB9CQ30437948-7786096C-FF18-488A-B5EE-624FB27D7AD4Q30998192-1CEEA38A-9A36-465D-A795-11E0E1205E13Q33795144-234A333D-A727-4D38-91FF-AD87499A2219Q33894236-5C753C1C-AE1A-4D24-9B73-B5C14BA26F34Q33908201-B3E91361-C406-455C-844D-37E09036851DQ33968252-5495D269-524D-492D-8775-119D2C0CD757Q34493230-0A1832B1-D005-46EC-BEBB-4E3D71BB258DQ34805156-8FB74D80-0A58-4C1A-829B-CAC4A3B82EF5Q35044435-340AC5C1-E2E7-4290-9685-03B760ED586CQ35553039-54CEEB5D-CC25-4742-8EC4-8D99289830FCQ35603175-FCF80223-4316-4113-9B87-B4EC4632825AQ35639988-E357EE91-D018-45DB-9C06-FC458643195BQ35656129-26F3E39F-5A0D-4B75-8A0D-BC885D386D85Q36240868-F6B160B7-B7D6-4A5E-8A44-8CA1222BEB31Q36458482-CF24892A-7DF5-4184-AD2E-7062324379A3Q36489864-2A124FFC-D7FF-48C5-AC90-121640485DA1Q36536417-03A27F9E-CF69-433D-A686-2EEEF87B29B2Q36858313-346F1E06-0FEA-42B6-8070-929C4B2B32A4Q36940050-A52B5467-C228-4D92-9061-4D4E7FF9C20DQ36961152-88733F29-6ECF-4E36-A200-DBAED2C60858Q37119533-613DC89C-37AD-4E5D-8659-AB1CA6DAEB05Q37120788-914DBF1C-046F-4B57-BBAC-B2DAF372C8A2Q37132636-2091AB5D-A53C-4FD2-BE7A-B0662FA8AD4CQ37310621-161B5AD2-3B1A-48D3-901A-A845103B1F24Q38179520-4DA4DCF8-F6FD-478B-95A6-535ADA43DD09Q38190156-B4A0A75C-83F3-44EE-BB87-7AE4CA9037E6Q38256971-1D8FA63E-F38F-4D2F-9528-A8E796ACBFB2Q38343014-8C189258-B7FA-488A-9357-786581DBFF29Q38694463-AB8E86BB-94CA-4143-A1DA-9B70D19FC2BAQ38891507-891EFFB7-28A2-49D7-97A9-6FF3B68D0C11Q39060517-D701FAC4-7C2C-416C-ABA6-2EE2ACEF2A7EQ39236820-E769B11B-A6E4-4C10-9E70-7D3AE07FC409Q39384630-F6898EB6-772C-4970-9121-87D3415E38A2Q39385143-E8AC9FBE-5D53-4349-92BB-1C99DEAD3D03
P2860
Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders.
@ast
Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders.
@en
type
label
Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders.
@ast
Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders.
@en
prefLabel
Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders.
@ast
Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders.
@en
P2093
P1433
P1476
Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders.
@en
P2093
Jack van Horssen
Lambert P W J van den Heuvel
Marcel M Verbeek
Robert M W de Waal
P304
P356
10.1016/S1474-4422(03)00484-8
P577
2003-08-01T00:00:00Z